Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corporation due to a class action complaint related to the company's fiduciary duties and misleading revenue expectations for its TAVR platform [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Edwards who held shares between February 6, 2024, and July 24, 2024, following a class action complaint filed on December 13, 2024 [1]. - The law firm is encouraging affected investors to discuss their legal rights and options [1][5]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024, significantly lowering its revenue guidance for the TAVR platform for the full fiscal year [3]. - The company attributed the decline in TAVR performance to increased pressure on hospital workflows from the growth of other structural heart therapies, including its own TMTT [3]. - Following the announcement, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in one day [4]. Group 3: Company Strategy - During the second quarter, Edwards announced three acquisitions aimed at enhancing treatments alternative to TAVR, indicating a recognition of the potential slowdown in TAVR growth [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Cummins Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The investigation is focused on whether Cummins' board of directors has breached their fiduciary duties to the company [1]. - A class action complaint was filed against Cummins on March 15, 2024, covering a class period from April 30, 2019, to December 21, 2023 [1]. Group 2: Allegations in the Lawsuit - The lawsuit claims that Cummins made materially false and misleading statements regarding its compliance with environmental regulations [2]. - It is alleged that Cummins continued to produce engines with unlawful emission defeating devices from 2019 to 2023, contradicting their assurances made post-April 2019 [2]. - The company is accused of understating its legal and regulatory risks while overstating its commitment to environmental protection [2].

Core Viewpoint - Julie & Holleman LLP is investigating the proposed acquisition of WideOpenWest, Inc. by Crestview Partners and DigitalBridge Investments, citing conflicts of interest and a belief that the acquisition price of $5.20 per share is undervalued [1][4]. Company Overview - WideOpenWest, Inc. (WOW!) is a leading broadband provider in the U.S., operating in 20 markets across the Midwest and Southeast [2]. - Wall Street analysts have set an average one-year stock price target of $5.65 per share for WOW!, with a high target of $6.50 per share [2]. Acquisition Details - On August 11, 2025, WOW! announced an agreement to be taken private at a price of $5.20 per share, with Crestview Partners, which owns 37% of WOW!'s stock, partnering with DigitalBridge to acquire the remaining shares [3]. Legal Concerns - Julie & Holleman LLP is pursuing potential legal claims regarding the fairness of the acquisition deal, highlighting concerns over conflicts of interest as key insiders will remain with the company while public shareholders are being cashed out at a price below the company's true value [4].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into MeridianLink, Inc. regarding potential breaches of fiduciary duties by its board members in relation to the proposed sale to Centerbridge Partners, which may undervalue the company’s shares [1][6]. Company Overview - MeridianLink has entered into a definitive merger agreement with Centerbridge Partners, where shareholders will receive $20.00 in cash per share [6]. - The proposed merger price is significantly lower than MeridianLink's 52-week high of $25.33 per share, despite positive projections for the company's sales and revenue growth from Wall Street analysts [6]. Legal Context - The investigation by Johnson Fistel is aimed at assessing whether the board's actions in the sale process are in the best interest of shareholders [1]. - Shareholders who believe the deal undervalues their investment are encouraged to participate in the investigation [3]. Firm Background - Johnson Fistel, PLLP is recognized as a leading shareholder rights law firm with a strong track record in securities class action lawsuits, having recovered approximately $90.725 million for clients [4].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of STAAR Surgical Company regarding the proposed sale to Alcon, which may undervalue the company’s shares [1][2]. Company Overview - STAAR Surgical has entered into a definitive merger agreement with Alcon, where shareholders will receive $28.00 in cash per share [5]. - The merger consideration is significantly lower than STAAR Surgical's 52-week high of $41.00 per share, despite positive projections for the company's sales and revenue growth from Wall Street analysts [5]. Legal Context - Johnson Fistel, PLLP is a recognized shareholder rights law firm that represents both individual and institutional investors in derivative and class action lawsuits [2][3]. - The firm has a history of recovering substantial amounts for clients, having secured approximately $90.7 million in previous cases [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Humana Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the board of directors during the specified class period [2][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit against Humana alleges that the company made false or misleading statements regarding its adjusted earnings-per-share, particularly downplaying the impact of increased medical costs from pent-up demand for healthcare services [4]. - On June 13, 2023, UnitedHealth Group Inc. reported higher outpatient care activity, which led to a significant drop of over 11% in Humana's stock price [5]. - Following a report on June 16, 2023, indicating higher than anticipated non-inpatient utilization trends, Humana's stock price fell again, reflecting investor concerns [6]. - On January 18, 2024, Humana disclosed an increase in its benefits expense ratio to approximately 91.4% for Q4 2023, resulting in a nearly 8% decline in stock price [7]. - The announcement of a loss of $4.42 per share for Q4 2023 on January 25, 2024, due to higher inpatient utilization and expected persistent medical costs, caused Humana's stock to drop nearly 12% [8]. Group 2: Company Overview - Humana is a health insurance company that provides medical benefit plans to its members [3].

About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep ...

Group 1 - The proposed merger agreement between Chart Industries and Baker Hughes involves Baker Hughes acquiring all outstanding shares of Chart Industries for $210 in cash per share [2] - Chart Industries has strong near-term earnings and revenue projections, with at least one equity analyst valuing the company at $250 per share, indicating the proposed buyout price may undervalue the company [2] - Johnson Fistel, PLLP has initiated an investigation into whether the board members of Chart Industries breached their fiduciary duties regarding the proposed sale [1] Group 2 - Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that represents individual and institutional investors in shareholder derivative and securities class action lawsuits [4] - The firm has been recognized as a top plaintiffs' securities law firm in the United States, having recovered approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel [5]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Skyworks Solutions, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the period from August 8, 2023, to February 5, 2025 [1][2]. Financial Performance - On February 5, 2025, Skyworks announced its financial results for Q1 of fiscal year 2025, providing lower-than-expected revenue guidance for Q2, attributing this to an intensified competitive landscape [3]. - Following the announcement, Skyworks' stock price plummeted from $87.08 per share to $65.60 per share, marking a decline of over 24% in just one day [3]. Legal Context - The class action complaint filed on March 3, 2025, claims that the defendants misled investors regarding Skyworks' expected revenue for fiscal year 2025, expressing confidence in the company's growth potential and mobile business expansion [2]. - The law firm is encouraging long-term stockholders who suffered losses to contact them for discussions regarding their legal rights [1][4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Krispy Kreme, Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the board of directors during a specified class period [1][2]. Group 1: Class Action Lawsuit Details - The class action lawsuit claims that Krispy Kreme made false or misleading statements regarding the demand for its products at McDonald's locations, which significantly declined after the initial marketing launch [2]. - It is alleged that the declining demand at McDonald's contributed to a decrease in average sales per door per week and that the partnership with McDonald's was not profitable, posing risks to the continuation of this partnership [2]. - The lawsuit also states that Krispy Kreme would pause its expansion into new McDonald's locations due to these issues [2]. Group 2: Financial Performance - On May 8, 2025, Krispy Kreme reported its first quarter 2025 financial results, revealing net revenue of $375.2 million, a decline of 15.3% compared to the previous year [3]. - The company also reported a net loss of $33.4 million, a significant increase from the prior year's net loss of $6.7 million [3]. - Following the release of these financial results, Krispy Kreme announced it would reassess its deployment schedule with McDonald's and withdrew its prior full-year outlook, citing uncertainty around the McDonald's deployment schedule [3]. - The announcement led to a nearly 25% drop in Krispy Kreme's share price [3].